Abstract 522P
Background
Adding an immune checkpoint inhibitor (ICI) to chemotherapy has demonstrated efficacy in treating extensive-stage small cell lung cancer (ES-SCLC). However, patients with idiopathic interstitial pneumonia (IIP) have a higher risk of developing pneumonitis associated with anticancer therapy. We conducted a multicenter, single-arm trial to evaluate the safety and efficacy of durvalumab plus etoposide and carboplatin for patients with ES-SCLC and mild IIP.
Methods
Eligible patients were those who had not been previously treated with ES-SCLC and mild IIPs. Mild IIP was defined as predicted vital capacity (VC) ≥80%; no collagen vascular disease-associated antibodies; and chest high-resolution computed tomography image revealed a probable UIP, indeterminate for UIP, or alternative diagnosis pattern. The primary endpoint was severe-pneumonitis-free (SPF) rate, which was defined as the rate of patients who did not develop Grade 3 or higher pneumonitis. The study treatment was feasible if the SPF rate was 90% or more, and grade 5 pneumonitis was found within one patient.
Results
In total, 22 cases were enrolled, and 21 were included in the analysis. The median age was 74 years (range, 65–82). Most patients had stage Ⅳ disease (90%) and Eastern Cooperative Oncology Group Performance Status of 1 (67%). The median %VC was 96.1% (range 81.3–117.8). Thirteen patients displayed a probable UIP pattern, while 8 were indeterminate for UIP pattern. The SPF rate was 95.2% (20/21). The incidence of pneumonitis was 9.5% (2/21) for all grades. One patient had grade 5 pneumonitis.
Conclusions
Durvalumab plus etoposide and carboplatin can be a feasible treatment option for patients with ES-SCLC and mild IIPs.
Clinical trial identification
The Japan Registry of Clinical Trials: jRCTs051200109.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca PLC.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
441P - The prophylactic efficacy of telpegfilgrastim, a Y-shape branched pegylated G-CSF in patient with chemotherapy-induced neutropenia: A multicenter, randomized phase III study
Presenter: Xinshuai Wang
Session: Poster Display
Resources:
Abstract
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract